“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin’s Ankleshwar Facility Wins Frost & Sullivan’s India Manufacturing Excellence Awards 2019
Mumbai, December 24, 2019: Pharma major Lupin Limited announced that its Ankleshwar facility has been awarded “Future Ready Factory of the Year | Pharmaceutical Sector, Large Business,” by Frost & Sullivan’s India Manufacturing Excellence Awards (IMEA) 2019. The 2019 evaluation was done on the basis of an organisations’ Manufacturing Capability, Extended Supply Chain Reliability and Technology Adoption.
On the occasion, Rajendra B Chunodkar, President — Manufacturing Operations, Lupin Limited said, “We are delighted to receive the award for Future Ready Factory of the Year. We strive to benchmark our manufacturing processes to the best practices in the world and we will continuously strive to get better and emerge successfully in a competitive market.”
IMEA was conceptualised with a mission “to recognise Indian Manufacturing capability and assess its global competitiveness” and has been the premier platform to identify Future Ready Factories in the country. The awards recognise best-in-class innovation, success stories and stellar performances exhibited in the manufacturing industry.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM) and 6th largest company in the Indian pharmaceutical market (IQVIA MAT September 2019).
For the financial year ended March 31, 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.
For further information or queries please contact:
Arvind Bothra
Head – Investor Relations and M&A / Corporate Communications
Email: arvindbothra@lupin.com
Ph: +91-22-66408237
